Anthony J. Polverino's most recent trade in Brainstorm Cell Therapeutics, Inc. was a trade of 24,000 Common Stock done . Disclosure was reported to the exchange on Jan. 1, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Brainstorm Cell Therapeutics | Anthony J. Polverino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jan 2025 | 24,000 | 25,730 (0%) | 0% | 0 | Common Stock | |
| Brainstorm Cell Therapeutics | Anthony J. Polverino | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Feb 2022 | 3,882 | 25,960 (0%) | 0% | 0 | Common Stock | |
| Zymeworks BC Inc | Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 15.00 per share. | 31 Aug 2021 | 4,900 | 36,333 (0%) | 0% | 15 | 73,500 | Common Shares |
| Zymeworks BC Inc | Anthony J. Polverino | Chief Scientific Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2021 | 4,900 | 77,600 | - | - | Stock Option (Right to Buy) | |
| Zymeworks BC Inc | Anthony J. Polverino | Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 29.49 per share. | 06 Jul 2021 | 454 | 31,433 (0%) | 0% | 29.5 | 13,388 | Common Shares |